- Home
- IPSC vs TTGT Comparison
IPSC vs TTGT Comparison
Compare IPSC & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPSC | TTGT |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.2M | 344.2M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | IPSC | TTGT |
|---|---|---|
| Price | $2.15 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.50 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.4M | 378.2K |
| Earning Date | 05-14-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | $4.45 |
| Revenue Next Year | N/A | $2.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.34 | $3.41 |
| 52 Week High | $2.97 | $9.92 |
Technical Indicators
Market Signals| Indicator | IPSC | TTGT |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 53.29 |
| Support Level | $0.49 | $3.42 |
| Resistance Level | $2.68 | $5.96 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 27.18 | 99.01 |
Price Performance
Historical ComparisonAbout IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.